BDX - BD CerTest Biotec announce commercial launch of monkeypox test

• Becton, Dickinson and Company ( NYSE: BDX ), or BD, and CerTest Biotec on Wednesday said their monkeypox PCR detection test was now commercially available outside of the U.S. for use in research applications by laboratories.
• The test, called the CerTest VIASURE Monkeypox molecular test, was developed using the BD MAX System.
• "Speed is of the essence when responding to what the World Health Organization has declared a global health emergency," said CerTest Biotec managing director Nelson Fernandes. "We hope this new test will boost capacity for monkeypox research, ultimately helping quell the spread of the disease."
• The WHO designated the current monkeypox outbreak a public health emergency of international concern on Saturday.
• BDX stock closed +0.6% at $244.15 on Tuesday.

For further details see: